Acute Erythroleukemia Morphology Does Not Confer an Unfavourable Prognosis in Itself. Results of a Subgroup Analysis of the Prospective Randomized AML96-, AML2003 and AML60+ Studies of the Study Alliance Leukemia (SAL)

Stefani Parmentier, MD, Michael Kramer, Katharina Koch, Brigitte Mohr, PhD, Christian Klesse, Christian Thiede1, Christoph Röllig, Mathias Hänel, MD, Norbert Schmitz, MD, Kerstin Schäfer-Eckart, Walter E. Aulitzky, Wolfgang E. Berdel, MD, Hubert Serv

Author address: 

Universitätsklinikum Dresden, Medizinische Klinik und Poliklinik I, Dresden, Germany

Abstract: 

Introduction Acute erythroleukemia (AEL) represents a rare type of acute myeloid leukemia accounting for less than 5% of all cases. So far, according to WHO classification this AML entity is thought to have a poor prognosis in itself. Design 3267 patients with newly diagnosed AML were treated according to the protocols of the AML96, AML2003 or AML60+ studies of the Study Alliance Leukemia (SAL). 116 of these patients had acute erythroleukemia (AEL). The median age both for patients with AEL and non-AEL was 57 years. We assessed the influence of relevant clinical and demographic parameters, FLT3-ITD, NPM1 status and cytogenetics on complete remission rates (CR), overall survival (OS) and event free survival (EFS) separately in AEL and non-AEL patients. Results Compared to non-AEL AML, significantly more AEL were due to secondary causes than non-AEL AML (31% versus 20.4%; p=0.024). NPM1 mutations were found in 11.1% (out of 99) of the patients with AEL and in 32.8% (out of 2693) of the patients with non-AEL AML (p 0.8 were found less frequently in AEL (FLT3-ITD mutation in 4.9% vs 23.3% ; p=0.001; FLT3-ITD ratio >0.8 in 0% vs. 33.4%; p/= 3 independent aberrations) were found more often in the AEL cohort (14.8%, 10.3% and 26.7%) than in the non-AEL AML cohort (8.9%, 5% and 13.2%) (p=0.036, p= 0.01 and p
2012

abstract No: 

1481

Full conference title: 

American Society of Hematology 2012
    • ASH 54th (2012)